公开(公告)号：US20200171092A1

公开(公告)日：2020-06-04

申请号：US16620655

申请日：2018-05-08

Applicant: OSAKA UNIVERSITY ,  ROHTO PHARMACEUTICAL CO., LTD.

Inventor： Yoshiki Sawa ,  Shigeru Miyagawa ,  Daisuke Kajita ,  Hayato Kurata ,  Kotoe Tamada ,  Hiroyuki Nishida

IPC: A61K35/28 ,  A61K9/14 ,  A61K38/20 ,  A61K38/18 ,  A61K38/17 ,  A61P9/10

Abstract: The purpose of the present invention is to provide a therapeutic agent for dilated cardiomyopathy disease which produces excellent effects in the treatment of dilated cardiomyopathy (DCM) and provides a given benefit to a large number of patients. The present invention is a therapeutic agent for dilated cardiomyopathy comprising at least one selected from the group consisting of mesenchymal stem cell and microparticles derived from the mesenchymal stem cell. It is preferable that the mesenchymal stem cell is a cell having the ability to contain or secrete microparticles, that the microparticles have an average particle size of 1000 nm or less, and that they are exosomes.

公开(公告)号：US20190255116A1

公开(公告)日：2019-08-22

申请号：US16343330

申请日：2017-10-13

Applicant: OSAKA UNIVERSITY ,  ROHTO PHARMACEUTICAL CO., LTD.

Inventor： Yoshiki Sawa ,  Shigeru Miyagawa ,  Daisuke Kajita ,  Kotoe Tamada

IPC: A61K35/28 ,  A61K9/06 ,  A61K38/48 ,  A61K38/36 ,  A61K9/08 ,  A61P9/10

Abstract: The present invention addresses the problem of providing a disease-treating agent which exerts an excellent effect in treating diseases requiring an emergency surgery such as heart failure and which is efficacious at a certain level for a large number of patients. The present invention pertains to a kit for preparing a disease-treating agent, said kit comprising a) a fibrinogen solution, b) a thrombin solution and c) mesenchymal stem cells, in separate forms respectively. It is preferred that c) the mesenchymal stem cells are allogeneic to a subject to be treated. Also, the present invention pertains to a kit for preparing a disease-treating agent, said kit being to be used by, when in use, suspending c) the mesenchymal stem cells in either a) the fibrinogen solution or b) the thrombin solution, and then spraying the cell suspension thus obtained directly to a disease site substantially simultaneously with either b) the thrombin solution or a) the fibrinogen solution that is not used in the suspending step.

公开(公告)号：US20230032293A1

公开(公告)日：2023-02-02

申请号：US17881413

申请日：2022-08-04

Applicant: ROHTO PHARMACEUTICAL CO., LTD.

Inventor： Yoshiki Sawa ,  Shigeru Miyagawa ,  Daisuke Kajita ,  Kotoe Tamada

IPC: A61K35/28 ,  A61P9/10 ,  A61K9/06 ,  A61K9/08 ,  A61K38/36 ,  A61K38/48 ,  A61K9/12 ,  A61K9/10 ,  A61P9/00 ,  A61K38/00 ,  A61P27/02 ,  A61P43/00

Abstract: Methods are described for treating a heart disease, comprising suspending c) mesenchymal stem cells in either a) a fibrinogen solution or b) a thrombin solution, thereby obtaining a cell suspension, and directly spraying the cell suspension on a disease site substantially at the same time with the other of a) the fibrinogen solution or b) the thrombin solution that is not used in the suspending.

公开(公告)号：US12226436B2

公开(公告)日：2025-02-18

申请号：US16071123

申请日：2017-01-18

Applicant: ROHTO PHARMACEUTICAL CO., LTD

Inventor： Daisuke Kajita ,  Satsuki Fukushima ,  Shigeru Miyagawa ,  Yoshiki Sawa

IPC: A61K35/28 ,  A61K35/35 ,  A61K35/51 ,  A61K35/545

Abstract: It has been found that a cell cluster obtained by causing just isolated cells to adhere to each other secretes adiponectin after transplantation to the heart, and thereby has an excellent therapeutic effect on heart disease.

公开(公告)号：US12084683B2

公开(公告)日：2024-09-10

申请号：US16702755

申请日：2019-12-04

Applicant: TERUMO KABUSHIKI KAISHA ,  OSAKA UNIVERSITY

Inventor： Fumiya Ohashi ,  Hiroko Iseoka ,  Yoshiki Sawa ,  Shigeru Miyagawa

IPC: C12N5/077 ,  A61K35/34 ,  C12N5/00 ,  C12N5/071 ,  C12N5/073 ,  C12N5/0735

CPC classification number: C12N5/0657 ,  A61K35/34 ,  C12N5/0093 ,  C12N5/0602 ,  C12N5/0603 ,  C12N5/0606 ,  C12N2501/115 ,  C12N2501/15 ,  C12N2501/155 ,  C12N2501/16 ,  C12N2501/998 ,  C12N2506/45

Abstract: A method for producing a cell culture containing desired cells is provided. The desired cells are induced to be differentiated from pluripotent stem cells. The method includes seeding a cell population by dispersing embryoid bodies obtained by inducing differentiation from the pluripotent stem cells to the desired cells. The embryoid bodies are dispersed at a density reaching confluence or higher.

公开(公告)号：US11969459B2

公开(公告)日：2024-04-30

申请号：US16477878

申请日：2018-01-26

Applicant: StemRIM Inc. ,  OSAKA UNIVERSITY

Inventor： Katsuto Tamai ,  Yoshiki Sawa ,  Shigeru Miyagawa ,  Takashi Kido ,  Takasumi Goto ,  Takehiko Yamazaki

IPC: A61K38/00 ,  A61K38/19 ,  A61P9/10 ,  C07K14/00

CPC classification number: A61K38/19 ,  A61P9/10

Abstract: The present inventors have found that HMGB1 fragment peptides having a particular amino acid sequence exhibit the effects of improvement of cardiac function, inhibition of cardiomyocyte hypertrophy, inhibition of myocardial fibrosis, and promotion of angiogenesis in an animal model of dilated cardiomyopathy, that the particular HMGB1 fragment peptides also exhibit the effects of improvement of cardiac function, inhibition of cardiomegaly, inhibition of cardiomyocyte hypertrophy, inhibition of myocardial fibrosis, and promotion of angiogenesis in an animal model of ischemic cardiomyopathy caused by old myocardial infarction, and that the particular HMGB1 fragment peptides exhibit the effects of inhibition of cardiomyocyte hypertrophy and inhibition of myocardial fibrosis in an animal model of hypertensive cardiomyopathy. Based on these findings, pharmaceutical compositions are provided for the prevention and/or treatment of cardiomyopathy and old myocardial infarction and chronic heart failure resulting therefrom, which comprise an HMGB1 fragment peptide having a particular amino acid sequence.

公开(公告)号：US11124770B2

公开(公告)日：2021-09-21

申请号：US15594011

申请日：2017-05-12

Applicant: TERUMO KABUSHIKI KAISHA ,  OSAKA UNIVERSITY

Inventor： Hiroko Iseoka ,  Yoshiki Sawa ,  Shigeru Miyagawa ,  Satsuki Fukushima

IPC: C12N5/077 ,  A61K35/34 ,  A61K35/12

Abstract: A sheet-shaped cell culture is disclosed that includes myocardial cells derived from pluripotent stem cells and has excellent functional properties. A sheet-shaped cell culture obtained by culturing a cell population that includes myocardial cells derived from pluripotent stem cells, wherein the proportion of the number of the myocardial cells derived from pluripotent stem cells to the total number of cells in the cell population is 50% to 70%; a method of producing the sheet-shaped cell culture; a composition including the sheet-shaped cell culture; and a method of treating a disease using the sheet-shaped cell culture or the composition.

公开(公告)号：US20210113464A1

公开(公告)日：2021-04-22

申请号：US16766992

申请日：2017-11-27

Applicant: Osaka University ,  Cardio Incorporated

Inventor： Yoshiki Sawa ,  Shigeru Miyagawa ,  Yoshiki Sakai ,  Yasuhiro Yanagi

IPC: A61K9/127 ,  A61K31/4406

Abstract: The present invention provides a clinically applicable, safe and convenient, pharmaceutical composition for disease site-specific treatment. The pharmaceutical composition for disease site-specific treatment comprises a stealth liposome having a prostaglandin I2 receptor agonist encapsulated therein.

公开(公告)号：US09597436B2

公开(公告)日：2017-03-21

申请号：US14429565

申请日：2013-09-13

Applicant: Osaka University ,  Nipro Corporation ,  Ono Pharmaceutical Co., Ltd.

Inventor： Yoshiki Sawa ,  Shigeru Miyagawa ,  Satsuki Fukushima ,  Atsuhiro Saito ,  Yoshiki Sakai ,  Kazuhisa Matsuda ,  Takayuki Maruyama

IPC: A61K31/16 ,  A61K31/4406 ,  A61K31/343 ,  A61K9/16 ,  A61K9/00 ,  A61L31/14 ,  A61L31/16

CPC classification number: A61L31/16 ,  A61F2/2481 ,  A61K9/0024 ,  A61K9/16 ,  A61K9/1647 ,  A61K31/343 ,  A61K31/4406 ,  A61K47/42 ,  A61L17/005 ,  A61L17/12 ,  A61L17/145 ,  A61L31/06 ,  A61L31/10 ,  A61L31/146 ,  A61L31/148 ,  A61L2300/412 ,  A61L2300/622 ,  A61L2430/20 ,  C08L89/00 ,  C08L89/06 ,  C08L67/04

Abstract: Provided is an advanced heart failure treatment material, as a myocardial/cardiovascular regeneration device, that self-assembles, which can improve the universality and be used in an emergency by commercialization with no need of cell-culturing (cell-free) by controlling stem cells, and has a high therapeutic effect on the fundamental treatment of intractable cardiovascular diseases, in particular, advanced heart failure, in which not only the saving of lives but also improving the patient's quality of life (QOL) are urgent issues. The advanced heart failure treatment material includes a pharmaceutical agent, an agent holding for the pharmaceutical agent, and a myocardial support device.

公开(公告)号：US20160312188A1

公开(公告)日：2016-10-27

申请号：US14998446

申请日：2016-01-08

Applicant: OSAKA UNIVERSITY

Inventor： Akifumi Matsuyama ,  Hiroshi Komoda ,  Yoshiki Sawa ,  Yuzuru Kanakura

IPC: C12N5/071 ,  C12N5/077 ,  C12N5/0775

CPC classification number: C12N5/0676 ,  A61K35/12 ,  C12N5/0653 ,  C12N5/0667 ,  C12N5/0678 ,  C12N2500/25 ,  C12N2500/32 ,  C12N2500/33 ,  C12N2500/38 ,  C12N2501/115 ,  C12N2501/335 ,  C12N2503/02 ,  C12N2506/1384 ,  C12N2533/52 ,  G01N33/507

Abstract: A method of obtaining pancreatic endocrine cells from cells originating in an adipose tissue characterized by comprising culturing the adipose tissue-origin cells; the pancreatic endocrine cells that can be obtained thereby; a method of treating or preventing a disease caused by the hypofunction in pancreatic endocrine cells wherein the above-described pancreatic endocrine cells are used; a method of screening a substance capable of promoting or inhibiting the differentiation into pancreatic endocrine cells characterized by comprising adding a candidate substance to a medium in the course of culturing adipose tissue-origin cells to obtain the pancreatic endocrine cells; and so on.